Effects of bacterial lipopolysaccharide on serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma.
- Author:
Bin LUAN
1
;
Mei-Jing FENG
;
Jun-Ying QIAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Asthma; drug therapy; immunology; Female; Interleukin-4; blood; Interleukin-8; blood; Lipopolysaccharides; pharmacology; Mice; Mice, Inbred BALB C; Vascular Endothelial Growth Factor A; analysis; physiology
- From: Chinese Journal of Contemporary Pediatrics 2012;14(4):297-300
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the regulatory role of bacterial lipopolysaccharide (LPS ) in the development of bronchial asthma by examining the effects of LPS on serum IL-4, serum IL-8 and pulmonary vascular endothelial growth factor (VEGF) expression in mice with asthma.
METHODSTwenty-seven BALB/c mice were randomly assigned into control, asthma and LPS-treated asthma groups (n=9 each). Serum IL-4 and IL-8 concentrations were measured using ELISA. VEGF expression in lung tissues was examined using the immunohistochemical method.
RESULTSSerum IL-4 and IL-8 concentrations in the asthma group were significantly higher than in the control group (P<0.05). LPS treatment significantly decreased serum IL-4 and IL-8 concentrations compared with the asthma group (P<0.05), although levels were significantly higher than in the control group (P<0.05). Airway VEGF expression in the asthma group was significantly higher than in the control group (P<0.05). LPS treatment significantly decreased airway VEGF expression compared with the asthma group (P<0.05), although concentrations remained higher than in the control group (P<0.05).
CONCLUSIONSLPS can decrease serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma, and thus can possibly reduce both airway inflammation and airway vascular remodeling.
